Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• 100% of target Phase 2 population became transplant eligible after lasme-cel treatment

  80% confidence

• Expanded peak sales for lasme-cel could reach up to approximately $1.3 billion with label expansion to 2nd line and 1st line MRD+ consolidation

  80% confidence

• Peak gross sales for lasme-cel could reach up to approximately $700 million in 2035 in US, EU4, and UK markets

  80% confidence

• Approximately 1,100 B-ALL patients would be treated annually at peak sales

  80% confidence

• Cellectis is strengthening leadership in allogeneic CAR-T innovation with a transformative year ahead

  80% confidence

• Allogeneic approach enables attractive margins and drives CAR-T B-ALL market growth

  80% confidence

• TALEB technology shows no bias towards off-site C-to-T editing at CTCF binding sites in primary T cells

  80% confidence

• Promising data from core clinical product candidates demonstrates ability to induce deep and meaningful responses in areas of high unmet medical needs

  80% confidence

• CssDNA-edited HSPCs show higher engraftment propensity versus AAV-edited HSPCs in murine model

  80% confidence

Cited in these Via News reports

• Cellectis Bets on Off-the-Shelf CAR-T Revolution as $700M Peak Sales Forecast Puts Global Cell Therapy Race in Focus →
• China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →